BioSpace

Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease

Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.

By BioSpace

1 min read
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights